Navigation Links
Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Date:4/24/2012

NEW YORK, April 24, 2012 /PRNewswire/ -- A study released today by Genpact Limited (NYSE: G), a global leader in business process and technology management, has found that 2012 will see fundamental shifts in the life sciences sector, pushing companies to reconsider the traditional approaches to their business model.  The research sought to determine the key challenges and priorities facing the key functions within life sciences companies, including finance and accounting (F&A), finance administration and commercial operations. 

More than 100 senior directors and executive vice presidents in both financial and commercial operations at targeted life sciences and pharmaceutical companies were surveyed for this research, including a selection of in-depth interviews.  The research found that far-reaching changes in the approach to chronic diseases, medical technology, social networks, global health issues, large emerging markets and aging populations will have an enormous industry-wide impact, forcing life sciences companies to transform themselves in an atmosphere of increasing consumerization and tighter funding constraints.

Respondents indicated that they face a number of challenges in today's marketplace that are compelling them to respond with innovation in previously unexplored organizational areas. Historically well capitalized due in large part to blockbuster drugs and abundant pipelines, these companies are now confronted with the prospect of market share loss due to a number of factors: generic drug competition, regulatory pressure, insurance company price controls and shrinking R&D pipelines.

The results showed that 68% of respondents chose "cost reduction" as having the greatest potential impact on business in 2012, followed by pricing and reimbursement pressure (53%), new regulations (33%) and increased competition (24%). 

To meet the operational challenges they face in the current marketplace, life sciences companies have been taking a variety of approaches to retain capital availability and improve revenue performance, including a focus on growth in emerging markets, mergers and acquisitions, and cost-cutting measures. While these approaches have had some degree of success, the results have been mixed and will eventually fall prey to the law of diminishing returns.

Having noted the challenges, survey respondents overwhelmingly (88%) agreed that their firms were not prepared to handle the transformational changes taking place within their business models, expressing concern that overall culture remained opposed to change.  Over half of the respondents (55%) cited a lack of real-time information for operations as the number one barrier to improving organizational performance.
Additional barriers acknowledged by those surveyed include a lack of process standards and discipline (44%), a deficiency in integrated risk management (44%) and outdated information for strategic decision-making (42%).

"Pricing pressure, new operating models, entry into emerging markets, and the micro-segmentation of products are driving the need to modify cost structures and realign activities to address structural trends in the industry," said Balkrishan 'BK' Kalra, senior vice president and business leader, Life Sciences at Genpact. "With this in mind, life sciences companies must reassess their distribution models to have greater impact on their costs. This will not be enough, however, as the implementation of smarter technology, more streamlined financial processes, and insights from more intelligent data and analytics will be imperative for improving operations."

Genpact engaged Pilgrim Partners, an advisory and research firm, to conduct the field study and analyze the market data. The full reports on the findings can be accessed at the following links: Overcoming Obstacles to Transformation in the Finance Function and Transformation in Commercial Operations: Today's Life Sciences and Pharmaceutical Industry

About Genpact
Genpact Limited (NYSE: G), a global leader in business process and technology management services, leverages the power of smarter processes, smarter analytics and smarter technology to help its clients drive intelligence across the enterprise.  Genpact's Smart Enterprise Processes (SEP(SM)) framework, its unique science of process combined with deep domain expertise in multiple industry verticals, leads to superior business outcomes. Genpact's Smart Decision Services deliver valuable business insights to its clients through targeted analytics, reengineering expertise, and advanced risk management. Making technology more intelligent by embedding it with process and data insights, Genpact also offers a wide range of technology services.  Driven by a passion for process innovation and operational excellence built on its Lean and Six Sigma DNA and the legacy of serving GE for more than 15 years, the company's 55,000+ professionals around the globe deliver services to its more than 600 clients from a network of 58 delivery centers across 16 countries supporting more than 25 languages. For more information, visit www.genpact.com. Follow Genpact on Twitter, Facebook and LinkedIn. For more information:Gail Marold (Genpact Media Relations)Barbara Tate (For Genpact U.S.) Rupali Kathuria (For Genpact India)gail.marold@genpact.com

barbara.tate@ogilvy.com

rupali.kathuria@bm.com+1 919-345-3899+1 212-880-5338 

Phone: +91 124 441 7589
'/>"/>

SOURCE Genpact Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Program Launch By Structural Enhancement Corp.
2. Advanced Biologics Launches OsteoAMP® Structural at the 26th Annual Meeting of the North American Spine Society
3. Boston Scientific Strengthens Structural Heart Product Portfolio By Completing Acquisition of Atritech
4. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
5. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
6. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. R&D Trends: Depression - Clinical attrition driven by mature market conditions
9. Patent and Trademark Trends 2011: Thomson Reuters Evaluates the State of Global IP
10. Global Diagnostic Imaging Market Trends and Outlook
11. World Glucose Self-Testing Markets - Trends, Product Overviews, Market Drivers & Industry Participants - ReportsnReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... ... Data integration has been a pharma industry buzzword for the last few ... staff are still working in silos and are not aware of all the data ... more, and nearly one-third of qualified investigators may be overlooked. Innovations in data mapping ...
(Date:12/2/2019)... ... December 02, 2019 , ... Strong public health departments engaged ... and play. Striving to fulfill their crucial mission, more and more health departments ... the Public Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial ...
(Date:11/30/2019)... (PRWEB) , ... November 29, 2019 , ... ... breast cancer screening, that uses deep learning algorithms to automatically detect potential breast ... Annual Radiological Society of North America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... 06, 2019 , ... Lasair Aesthetic Health Sponsors Toys for Tots to Give Free Toys to ... Who Bring in Toys During the Holidays , Lasair Aesthetic Health is spreading holiday cheer ... who bring in a toy or toys worth more than 25-dollars, will get FIVE units ...
(Date:12/6/2019)... , ... December 06, 2019 , ... Dr. Scott Howell, ... program, recently published research on the health benefits of coconut oil in the 7 ... and Its Effects on the Cardiometabolic Profile: A Structured Literature Review,” led by Dr. ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... announced the Top 54 RHIT Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... Tex-OE, Opuntia Mesocarp Extract®, provides protection from disruptions to cells and tissue and ... the menace of Jet Lag, is available in a dietary supplement product called ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... UNC Health ... easily find their way around the campuses of UNC Medical Center in Chapel Hill ... two hospitals, parking garages, clinics and more. , The free interactive app, developed by ...
Breaking Medicine News(10 mins):